Advertisement

Molecular Biology Reports

, Volume 45, Issue 6, pp 1973–1980 | Cite as

Increased expression of microRNAs, miR-20a and miR-326 in PBMCs of patients with type 1 diabetes

  • Zahra Azhir
  • Fariba Dehghanian
  • Zohreh HojatiEmail author
Original Article

Abstract

Type 1 diabetes (T1D) is an autoimmune disorder which is characterized by autoimmune attack on β cells of pancreas and lack of insulin. The involvement of microRNAs (miRNAs) in the development of immune system and their differential expression in various autoimmune diseases including T1D have been well established. In this study, the association between expression levels of miR-20a, miR-326 and T1D were evaluated. The expression levels of miR-20a and miR-326 were measured in the PBMCs of 21 T1D patients and 16 healthy controls using qPCR method. In silico analysis was also performed on targetome of miR-20a and miR-326. Both miR-20a (p value: 0.015) and miR-326 (p value: 0.005) were upregulated in the PBMCs of T1D patients compared to healthy controls. Furthermore, different dysregulated miR326–mRNA and miR20a–mRNA interactions were also suggested using integrative computational analysis. The expression level of miR-20a and miR-326 indicates significant association with T1D which suggests the possible regulatory effects of these non-coding RNAs in T1D.

Keywords

MicroRNA Type 1 diabetes miR-20a miR-326 

Notes

Acknowledgements

This study was performed at the biology department of University of Isfahan and was funded by the graduate office of the University of Isfahan.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study is approved by the University of Isfahan review board (Agreement Number: 94/34330) and also the ethics committee of Shariati Hospital, Isfahan, Iran (Agreement Number: 154/92/23273). A written consent form was obtained from each patient according to the Declaration of Helsinki. A written informed consent was also obtained from healthy control subjects who were above the 16 years old. In addition, the blood samples of patients and healthy controls with age less than 16 years, were collected with full written informed parent’s consent and in compliance with the ethical protocol and standards of Shariati Hospital.

Supplementary material

11033_2018_4352_MOESM1_ESM.docx (122 kb)
Supplementary material 1 (DOCX 122 KB)

References

  1. 1.
    Tsai S, Shameli A, Santamaria P (2008) CD8+ T cells in type 1 diabetes. Adv Immunol 100:79–124PubMedGoogle Scholar
  2. 2.
    Santamaria P (2010) The long and winding road to understanding and conquering type 1 diabetes. Immunity 32(4):437–445PubMedGoogle Scholar
  3. 3.
    Todd JA (2010) Etiology of type 1 diabetes. Immunity 32(4):457–467PubMedGoogle Scholar
  4. 4.
    Polychronakos C, Li Q (2011) Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet 12(11):781–792PubMedGoogle Scholar
  5. 5.
    Dang MN, Buzzetti R, Pozzilli P (2013) Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes 29(1):8–18Google Scholar
  6. 6.
    Steck AK, Rewers MJ (2011) Genetics of type 1 diabetes. Clin Chem 57(2):176–185PubMedPubMedCentralGoogle Scholar
  7. 7.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297PubMedPubMedCentralGoogle Scholar
  8. 8.
    Cai Y et al (2009) A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinform 7(4):147–154Google Scholar
  9. 9.
    Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9(2):102–114PubMedGoogle Scholar
  10. 10.
    Xiao C, Rajewsky K (2009) MicroRNA control in the immune system: basic principles. Cell 136(1):26–36PubMedGoogle Scholar
  11. 11.
    O’Connell RM, Rao DS, Baltimore D (2012) microRNA regulation of inflammatory responses. Ann Rev Immunol 30:295–312Google Scholar
  12. 12.
    Jeker LT, Bluestone JA (2013) MicroRNA regulation of T-cell differentiation and function. Immunol Rev 253(1):65–81PubMedPubMedCentralGoogle Scholar
  13. 13.
    Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13(8):622–638PubMedGoogle Scholar
  14. 14.
    Guay C, Regazzi R (2013) Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9(9):513–521PubMedGoogle Scholar
  15. 15.
    Hezova R et al (2010) microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol 260(2):70–74PubMedGoogle Scholar
  16. 16.
    Nielsen LB et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012: 896362PubMedPubMedCentralGoogle Scholar
  17. 17.
    Salas-Pérez F et al (2013) MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology 218(5):733–737PubMedGoogle Scholar
  18. 18.
    Takahashi P et al (2014) MicroRNA expression profiling and functional annotation analysis of their targets in patients with type 1 diabetes mellitus. Gene 539(2):213–223PubMedGoogle Scholar
  19. 19.
    Dweep H et al (2011) miRWalk—database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44(5):839–847PubMedPubMedCentralGoogle Scholar
  20. 20.
    Dweep H, Gretz N (2015) miRWalk2. 0: a comprehensive atlas of microRNA-target interactions. Nat Methods 12(8):697–697PubMedPubMedCentralGoogle Scholar
  21. 21.
    Sebastiani G et al (2011) Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes 27(8):862–866Google Scholar
  22. 22.
    Irizarry RA et al (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264PubMedPubMedCentralGoogle Scholar
  23. 23.
    Wettenhall JM et al (2006) affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics 22(7):897–899PubMedGoogle Scholar
  24. 24.
    Lynn DJ et al (2008) InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol Syst Biol 4(1):218PubMedPubMedCentralGoogle Scholar
  25. 25.
    Mogilyansky E, Rigoutsos I (2013) The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ 20(12):1603–1614PubMedPubMedCentralGoogle Scholar
  26. 26.
    Du C et al (2009) MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 10(12):1252–1259PubMedPubMedCentralGoogle Scholar
  27. 27.
    Sun X-G et al (2016) Negative correlation between miR-326 and Ets-1 in regulatory T cells from new-onset SLE patients. Inflammation 39(2):822–829PubMedGoogle Scholar
  28. 28.
    Guan H et al (2013) MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis. Eur J Immunol 43(1):104–114PubMedPubMedCentralGoogle Scholar
  29. 29.
    Honardoost MA et al (2014) miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing–remitting multiple sclerosis. Gene 544(2):128–133PubMedGoogle Scholar
  30. 30.
    Gillespie KM (2006) Type 1 diabetes: pathogenesis and prevention. Can Med Assoc J 175(2):165–170Google Scholar
  31. 31.
    Baumjohann D, Ansel KM (2013) MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol 13(9):666–678PubMedPubMedCentralGoogle Scholar
  32. 32.
    Bronevetsky Y et al (2013) T cell activation induces proteasomal degradation of Argonaute and rapid remodeling of the microRNA repertoire. J Exp Med 210(2):417–432PubMedPubMedCentralGoogle Scholar
  33. 33.
    Wu T et al. (2012) Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation. Proc Natl Acad Sci USA 109(25):9965–9970PubMedGoogle Scholar
  34. 34.
    Ventura A et al (2008) Targeted deletion reveals essential and overlapping functions of the miR-17∼ 92 family of miRNA clusters. Cell 132(5):875–886PubMedPubMedCentralGoogle Scholar
  35. 35.
    Xiao C et al (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9(4):405–414PubMedPubMedCentralGoogle Scholar
  36. 36.
    Tsitsiou E, Lindsay MA (2009) microRNAs and the immune response. Curr Opin Pharmacol 9(4):514–520PubMedPubMedCentralGoogle Scholar
  37. 37.
    Heuts F, Edner NM, Walker LS (2017) Follicular T helper cells: a new marker of type 1 diabetes risk? Diabetes 66(2):258–260PubMedGoogle Scholar
  38. 38.
    Ueno H, Banchereau J, Vinuesa CG (2015) Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 16(2):142–152PubMedPubMedCentralGoogle Scholar
  39. 39.
    Walker L, Von Herrath M (2016) CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol 183(1):16–29PubMedGoogle Scholar
  40. 40.
    O’donnell KA et al (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043):839–843PubMedGoogle Scholar
  41. 41.
    Sylvestre Y et al (2007) An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 282(4):2135–2143PubMedGoogle Scholar
  42. 42.
    Murga M et al (2001) Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 15(6):959–970PubMedGoogle Scholar
  43. 43.
    Wang J et al (2010) Bmp signaling regulates myocardial differentiation from cardiac progenitors through a MicroRNA-mediated mechanism. Dev Cell 19(6):903–912PubMedPubMedCentralGoogle Scholar
  44. 44.
    Narushima M et al (2005) A human β-cell line for transplantation therapy to control type 1 diabetes. Nat Biotechnol 23(10):1274–1282PubMedGoogle Scholar
  45. 45.
    Du Y et al (2016) miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB. Tumor Biol 37(1):1261–1269Google Scholar
  46. 46.
    Donath MY et al (2003) Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81(8):455–470PubMedGoogle Scholar
  47. 47.
    Reddycherla AV et al (2015) miR-20a inhibits TCR-mediated signaling and cytokine production in human naive CD4+ T cells. PLoS ONE 10(4):e0125311PubMedPubMedCentralGoogle Scholar
  48. 48.
    Ng T et al (2013) Regulation of adaptive immunity; the role of interleukin-10. Front Immunol 4:129PubMedPubMedCentralGoogle Scholar
  49. 49.
    Snowhite IV et al. (2017) Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. Diabetologia 60(8):1409–1422PubMedPubMedCentralGoogle Scholar
  50. 50.
    Cox MB et al (2010) MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. PLoS ONE 5(8):e12132PubMedPubMedCentralGoogle Scholar
  51. 51.
    Teruel R et al (2011) Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 9(10):1985–1992PubMedGoogle Scholar
  52. 52.
    Carlsen AL et al (2013) Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum 65(5):1324–1334PubMedGoogle Scholar
  53. 53.
    Vereecke L, Beyaert R, van Loo G (2011) Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 39(4):1086–1091PubMedGoogle Scholar
  54. 54.
    Størling J, Pociot F (2017) Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis. Genes 8(2):72PubMedCentralGoogle Scholar
  55. 55.
    Duan R et al (2010) Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS. Ann Rheum Dis 69(9):1724–1729PubMedGoogle Scholar
  56. 56.
    Poy MN et al (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432(7014):226–230PubMedGoogle Scholar
  57. 57.
    Corvol J-C et al. (2008) Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 105(33):11839–11844PubMedGoogle Scholar
  58. 58.
    Łuczyński W et al (2009) Diminished expression of ICOS, GITR and CTLA-4 at the mRNA level in T regulatory cells of children with newly diagnosed type 1 diabetes. Acta Biochim Pol 56(2):361–370PubMedGoogle Scholar
  59. 59.
    Ji N, Sosa RA, Forsthuber TG (2011) More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases. Immunotherapy 3(3):435–441PubMedPubMedCentralGoogle Scholar
  60. 60.
    Barrett JC et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41(6):703–707PubMedPubMedCentralGoogle Scholar
  61. 61.
    Hunter K et al (2007) Interactions between Idd5. 1/Ctla4 and other type 1 diabetes genes. J Immunol 179(12):8341–8349PubMedGoogle Scholar
  62. 62.
    Noble JA, Valdes AM (2011) Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 11(6):533PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Division of Genetics, Department of Biology, Faculty of SciencesUniversity of IsfahanIsfahanIran

Personalised recommendations